...
首页> 外文期刊>Medical oncology >Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients
【24h】

Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients

机译:乳腺癌PIK3CA基因突变的分子评价:频率,分布模式的测定及其与印度患者临床病理学发现的关系

获取原文
获取原文并翻译 | 示例
           

摘要

Somatic mutations in the PIK3CA gene are common in breast cancer and represent a clinically useful marker for prognosis and therapeutic target. Activating mutations in the PI3K p110 catalytic subunit (PIK3CA) have been identified in 18-40 % of breast carcinomas. In this study, we evaluated PIK3CA mutation in 185 Indian breast cancer patients by direct DNA sequencing. PIK3CA mutations were observed in 23.2 % (43/185) of breast tumor samples. PIK3CA mutations were more frequent exon 30 (76.8 %) than in exon 9 (23.2 %). Mutations were mostly clustered within two hotspot region between nucleotides 1624 and 1636 or between 3129 and 3140. Sequencing analysis revealed four different missense mutations at codon 542 and 545 (E542K, E545K, E545A and E545G) in the helical domain and two different amino acid substitutions at codon 1047 (H1047R and H1047L) in the kinase domain. None of the cases harbored concomitant mutations at multiple codons. PIK3CA mutations were more frequent in older patients, smaller size tumors, ductal carcinomas, grade II tumors, lymph node-positive tumors and non-DCIS tumors; however, none of the differences were significant. In addition, PIK3CA mutations were common in ER+, PR+ and HER2+ cases (30 %), and a comparatively low frequency were noted in triple-negative tumors (13.6 %). In conclusion, to our knowledge, this is the largest study to evaluate the PIK3CA mutation in Indian breast cancer patients. The frequency and distribution pattern of PIK3CA mutations is similar to global reports. Furthermore, identification of molecular markers has unique strengths and can provide insights into the pathogenic process of breast carcinomas.
机译:PIK3CA基因中的体细胞突变在乳腺癌中是常见的,并且代表临床上有用的标志物,用于预后和治疗靶标。在18-40%的乳腺癌中鉴定了PI3K P110催化亚基(PIK3CA)中的激活突变。在这项研究中,我们通过直接DNA测序评估了185名印度乳腺癌患者的PIK3CA突变。在23.2%(43/185)的乳腺肿瘤样品中观察到Pik3CA突变。 PIK3CA突变比在外显子9(23.2%)中更频繁的外显子30(76.8%)。在核苷酸1624和1636之间或3129和3140之间的两个热点区域内聚集在两个热点区域内。测序分析在螺旋结构域和两种不同的氨基酸取代中揭示了密码子542和545(E542K,E545K,E545A和E545G)的四种不同的畸形突变在激酶结构域中的密码子1047(H1047R和H1047L)。没有任何病例在多个密码子下呈现伴随突变。在老年患者中,PIK3CA突变更频繁,较小的肿瘤,导管癌,II级肿瘤,淋巴结阳性肿瘤和非直流肿瘤较小;但是,没有任何差异是显着的。此外,纤维3CA突变在ER +,PR +和HER2 +病例(30%)中常见,并且在三阴性肿瘤中注意到相对低的频率(13.6%)。总之,对于我们的知识,这是评估印度乳腺癌患者的Pik3CA突变的最大研究。 PIK3CA突变的频率和分布模式类似于全球报告。此外,分子标记的鉴定具有独特的优点,可以为乳腺癌的致病过程提供洞察。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号